ipilimumab,nivolumab
bms
['lung', 'nivo', 'sclc', 'nivolumab', 'nsclc', 'ipilimumab', 'check,mate,227']
five-year survival outcomes with nivolumab (nivo) plus ipilimumab (ipi) versus chemotherapy (chemo) as first-line (1l) treatment for metastatic non small cell lung cancer (nsclc): results from checkmate 227. #asco22
??????????????????

J-OSLER??????J-OSLER1???????????????

??????https://t.co/ZcsDggiURy…